NCT04726956View on ClinicalTrials.gov

A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC

CompletedOBSERVATIONAL
Enrollment

258

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

February 1, 2022

Conditions
Pancreatic Ductal Adenocarcinoma
Trial Locations (3)

200080

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Unknown

Changhai Hospital of Shanghai, Shanghai

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT04726956 - A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC | Biotech Hunter | Biotech Hunter